We are live on ! Find out more
DWTX

Dogwood Therapeutics

25 hedge funds and large institutions have $486K invested in Dogwood Therapeutics in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 5

47% more funds holding

Funds holding: 1725 (+8)

0.26% less ownership

Funds ownership: 0.55%0.28% (-0.26%)

13% less call options, than puts

Call options by funds: $65K | Put options by funds: $75K

90% less capital invested

Capital invested by funds: $4.8M → $486K (-$4.32M)

Holders
25
Holders Change
+8
Holders Change %
+47.06%
% of All Funds
0.43%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
3
Reduced
Closed
5
Calls
$65K
Puts
$75K
Net Calls
-$10K
Net Calls Change
-$10K
Name Holding Trade Value Shares
Change
Change in
Stake
TRCT
26
Tower Research Capital (TRC)
New York
-$6K -59 Closed
Royal Bank of Canada
27
Royal Bank of Canada
Ontario, Canada
+$141 +1 New
CG
28
Cutler Group
California
+$6.76K +48 New

DWTX Hedge Fund Activity: Q3 2022 in Review

25 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Dogwood Therapeutics (DWTX) for Q3 2022, worth a combined $486K — down 90% from $4.8M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new DWTX positions and 5 closed out — a net gain of 9 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Warberg Asset Management, opening a new position worth an estimated $1.13M. The largest seller was Masters Capital Management, exiting entirely with an estimated $2.75M sold.

  • 25 institutional investors held Dogwood Therapeutics (DWTX) as of Q3 2022, up from 17 in Q2 2022.
  • Funds reported $486K of Dogwood Therapeutics stock for Q3 2022, down 90% quarter-over-quarter.
  • 14 funds opened new Dogwood Therapeutics positions in Q3 2022 and 5 closed out, a net change of +9 holders.
  • The largest Dogwood Therapeutics buyer in Q3 2022 was Warberg Asset Management, an estimated $1.13M added.
  • The largest Dogwood Therapeutics seller in Q3 2022 was Masters Capital Management, an estimated $2.75M sold.

Based on aggregated 13F filings for Q3 2022.